A stability indicating LC method for rivastigmine hydrogen tartrate.

An isocratic, reversed-phase liquid chromatographic (RPLC) method was developed for the quantitative determination of Rivastigmine hydrogen tartrate, a cholinesterase inhibitor in bulk drugs and in pharmaceutical dosage forms. The developed method is also applicable for the related substance determination of Rivastigmine hydrogen tartrate in bulk drugs. The chromatographic separation was achieved on a Waters X Terra RP18 (250 mm x 4.6 mm, 5 microm) column using aqueous 0.01 M sodium-1-heptane sulphonate (pH: 3.0 with dilute phosphoric acid)-acetonitrile (72:28, v/v) as a mobile phase. The chromatographic resolution between Rivastigmine and its potential impurity, namely (S)-3-(1-dimethylaminoethyl) phenol (Imp 1) was found to be greater than four. Forced degradation studies were performed for Rivastigmine hydrogen tartrate bulk drug using acid (0.5 N hydrochloric acid), base (0.5 N sodium hydroxide), oxidation (3% hydrogen peroxide), heat (60 degrees C) and UV light (254 nm). No degradation was observed for Rivastigmine hydrogen tartrate except in base hydrolysis and the formed degradation product was found to be Imp 1. The mass balance of Rivastigmine hydrogen tartrate was close to 100 in all the stress conditions. The limit of detection (LOD) and limit of quantification (LOQ) of Imp 1 were found to be 100 and 300 ng/ml, respectively, for 10 microl injection volume. The percentage recovery of Imp 1 in bulk drug sample was ranged from 95.2 to 104.3. The active pharmaceutical ingredient was extracted from its finished dosage form (capsule) using water. The percentage recovery of Rivastigmine hydrogen tartrate was ranged from 99.2 to 101.3 and 98.6 to 101.5 in bulk and pharmaceutical formulation samples, respectively. Rivastigmine hydrogen tartrate sample solution and mobile phase were found to be stable for at least 48 h. The developed method was validated with respect to linearity, accuracy, precision, robustness and forced degradation studies prove the stability indicating power of the method.

Synthesis and structure-activity relationships of andrographolide analogues as novel cytotoxic agents.

Andrographolide 1, the cytotoxic agent of the plant Andrographis paniculata was subjected to semi-synthetic studies leading to the preparation of a number of potent and novel analogues. Of the analogues synthesized, while 8,17-epoxy andrographolide 6 retained the cytotoxic activity of 1, ester derivatives of 6 exhibited considerable improvement in activity. Lower activity was observed when the epoxy moiety in the triacetate 9, derived from 6 was modified. Synthesis and structure-activity relationships are discussed.

Synthesis and biological evaluation of thiophene [3,2-b] pyrrole derivatives as potential anti-inflammatory agents.

A series of thiophene [3,2-b] pyrrole derivatives were synthesized and evaluated their abilities to inhibit anti-inflammatory activity. In this series, substituent effects at the N-1, 2 and 5 positions of thiophene [3,2-b] pyrrole were examined. The results obtained are compared to those previously reported anti-inflammatory drugs like Tenidap sodium, Diclofenac sodium and Piroxicam. The results indicated the critical role of the group linked in the N-1 position and 2, 5 positions of thiophene [3,2-b] pyrrole with different functional groups.

Enantiomeric separation of the key intermediate of paroxetine using chiral chromatography.

A selective and reproducible chiral LC method has been developed for the separation and quantification of a key intermediate of paroxetine. The separation was achieved on three different chiral stationary phases, viz Chiralcel OD (250 x 4.6 mm, 10 microm), Chiralpak AD (250 x 4.6 mm, 10 microm) and Chiralcel OJ (250 x 4.6 mm, 10 microm). The method was validated on the Chiralcel OD phase using a mobile phase system consisting of hexane, isopropanol, and diethylamine in the ratio of 96:04:0.3 v/v/v. The precision (% R.S.D.) of the method was found to be less than 1.0 with the percentage recoveries of II B ranged from 96.0 to 103.4. The limits of detection and quantification of II B were found to be 2.0 and 7.5 microg/ml, respectively. The method was linear, with a correlation coefficient greater than 0.990, and the method was proved to be rugged.

Determination of lovastatin and simvastatin in pharmaceutical dosage forms by MEKC.

A micellar electrokinetic chromatographic (MEKC) method was developed for the quantification of lovastatin and simvastatin, cholesterol lowering agents in pharmaceutical dosage forms. Lovastatin and simvastatin were separated using an electrolyte system consisting of 12% acetonitrile (v/v) in 25 mM sodium borate buffer pH 9.3 containing 25 mM sodium dodecyl sulphate (SDS) with an extended light path capillary (48.5 cm x 50 microm i.d, 40 cm to detector). The method has been validated and proven to be rugged. Calibration curves were linear over the studied ranges with correlation coefficients greater than 0.996. A limit of detection of 3.2 microg/ml and a limit of quantitation of 10.6 microg/ml were estimated for both the drugs. The proposed method was found to be suitable and accurate for the determination of these drugs in commercial formulations.

Determination of celecoxib, a COX-2 inhibitor, in pharmaceutical dosage forms by MEKC.

A micellar electrokinetic chromatographic (MEKC) method was developed for the quantification of celecoxib, a COX-2 inhibitor in pharmaceutical dosage forms within the total analysis time of 7 min. The method has been validated and proven to be rugged. The quantification was carried out at 35 degrees C and 25 kV, using a 25 mM borate buffer (pH 9.3), 25 mM sodium dodecyl sulphate with an extended light path capillary (48.5 cm x 50 micro I.D., 40 cm to detector). Calibration curves were constructed for celecoxib (0.2-0.6 mg/ml) by the internal standard method with 2-nitro aniline as an internal standard (coefficient of correlation greater than 0.999). The intermediate precision (between day precision) of migration times and peak area ratios of celecoxib to internal standard were 1.44 and 1.58% R.S.D., demonstrates good reproducibility of the method. The method was applied to a commercial celecoxib formulation (Revibra, 100 mg) and the percentage recoveries were ranged from 93.0 to 98.4%.